Trevena Announces Pricing of Initial Public Offering
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,275,000 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Barclays Capital Inc. and Jefferies LLC are acting as joint book-running managers for the proposed offering. Canaccord Genuity Inc., JMP Securities LLC and Needham & Company, LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 30, 2014.
The offering is being made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at 888-603-5847 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced two differentiated product candidates into the clinic -- TRV027 to treat acute heart failure and TRV130 to treat moderate to severe acute pain intravenously. Trevena also plans to advance additional product candidates, including two preclinical programs focused on central nervous system indications.
For more information, please contact:
Roberto Cuca, senior vice president and chief financial officer
Andrea Rabney, president and chief executive officer
For media inquiries, please contact:
Eliza Schleifstein, 917-763-8106
Source: Trevena, Inc.
Released January 30, 2014